Project Grant R43GM161199
Award Date 9/1/25
Completion Date 8/31/26
Dollars Obligated $314K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Alameda, CA 94501, USA
Similar Awards
- This Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training program (CFDA 93.859) supports research to improve the efficiency of CRISPR gene editing in human pluripotent stem cells. The goal is to develop a novel carbon nanotube array technology that can efficiently transfer nucleic acids and proteins into these cells to enhance CRISPR-based gene editing and homology-directed recombination. The $275,045 award to Advanced Gene...
- This $295,924 Project Grant awarded by the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training program (CFDA 93.859) aims to develop and demonstrate a high-yield microfluidic device for the enrichment and capture of CD3+ T cells. This device is intended to improve the manufacturing of autologous and allogenic engineered cell therapies such as CAR-T, which currently have time-consuming and costly production processes. The key objectives are to (1)...
- This $302,671 federal Project Grant awarded on August 2, 2025 by the National Institute of General Medical Sciences (CFDA 93.859 Biomedical Research and Research Training program) to Andson Biotech Inc. aims to develop an innovative real-time mass spectrometry platform for in-process monitoring and cell state analysis of advanced cell therapies. The project seeks to address the challenges of variable quality and efficacy in cell therapies by enabling real-time measurement and control of critical...
- The National Science Foundation (NSF) awarded a $274,438 SBIR Phase I grant to Script Biosciences Inc. under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program. The project, titled "CASPLUS: A Safer, More Efficient, and Targeted Method of Deploying CRISPR In Vivo," aims to develop a platform technology that significantly reduces the potential inaccuracy of current gene editing techniques. The innovation targets the desired gene, increasing the safety and efficacy of...
- This $500,000 Project Grant from the National Science Foundation Division of Molecular and Cellular Biosciences, under the Biological Sciences federal grant program (CFDA 47.074), will support research to develop an end-to-end continuous manufacturing process for cell therapies using robotics and microfluidic technologies. The Georgia Tech Research Corporation will receive funding to create a more integrated workflow based on microfluidic device-enabled genetic engineering, cell expansion, and...
- This Project Grant award from the National Science Foundation's Social, Behavioral, and Economic Sciences (CFDA 47.075) program provides $250,000 to Old Dominion University Research Foundation (ODURF) to develop low-cost mRNA-based manufacturing technologies for Chimeric Antigen Receptor (CAR) T-cell therapies. The research aims to address critical issues with current CAR T-cell manufacturing, including safety concerns with viral gene transfer and high costs associated with centralized...
- This federal Project Grant award of $350,000 from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), aims to develop an affordable platform for rapid, high-resolution, single-cell analysis of the identity of human-induced pluripotent stem cells (hiPSCs). The platform will leverage technologies such as microscopic imaging of the epigenetic landscape, picowell arrays, and fluidic devices to enable affordable,...
- This $438,900 Project Grant was awarded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286). The grant funds research to develop a "three-cell (T-NK-macrophage) immunotherapy system" using chimeric antigen receptor (CAR) and synthetic cytokine receptor (SCR) technologies. The primary goal is to engineer the three immune cell types to function...
- This SBIR Phase I project, funded by a $305,000 award from the National Science Foundation's (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) program, aims to develop a microchip-based technology for complex, multidimensional cell reprogramming. The project seeks to create a miniaturized liquid and cell handling system that leverages acoustic-electric micro-vortices to precisely and sequentially deliver genetic molecules, making advanced cell engineering more accessible across...
- This federal Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), provides $350,000 in funding to Cisterna Biologics, Inc. to develop a novel mRNA production and purification process. The key objectives are to: Optimize psychrophilic (cold-adapted) RNA polymerases and synthetic promoters to minimize contaminants in mRNA synthesis, improving safety and efficacy for therapeutic use. Implement...